Rapport Therapeutics . Common Stock Stock Forecast

Buy or Hold candidate since Jun 12, 2026 Gain 6.72%

The Rapport Therapeutics, Inc. Common Stock stock price fell by -4.21% on the last day (Friday, 31st Jul 2026) from $42.78 to $40.98. During the last trading day the stock fluctuated 5.30% from a day low at $40.72 to a day high of $42.88. The price has fallen in 6 of the last 10 days and is down by -3.85% for this period. Volume has increased on the last day by 18 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 232 thousand shares were bought and sold for approximately $9.53 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 14.40% during the next 3 months and, with a 90% probability hold a price between $44.67 and $51.89 at the end of this 3-month period.

RAPP Signals & Forecast

A sell signal was issued from a pivot top point on Thursday, July 30, 2026, and so far it has fallen -4.21%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. Some positive signals were issued as well, and these may have some influence on the near short-term development. The Rapport Therapeutics, Inc. Common Stock stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $41.55. On a fall, the stock will find some support from the long-term average at approximately $40.14. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal.

Support, Risk & Stop-loss for Rapport Therapeutics, Inc. Common Stock stock

Rapport Therapeutics, Inc. Common Stock finds support from accumulated volume at $40.06 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $2.16 between high and low, or 5.30%. For the last week, the stock has had daily average volatility of 5.45%.

Our recommended stop-loss: $39.10 (-4.58%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 1 day ago.)

Trading Expectations (RAPP) For The Upcoming Trading Day Of Monday 3rd

For the upcoming trading day on Monday, 3rd we expect Rapport Therapeutics, Inc. Common Stock to open at $41.53, and during the day (based on 14 day Average True Range), to move between $39.76 and $42.20, which gives a possible trading interval of +/-$2.45 (+/-6.15%) up or down from last closing price. If Rapport Therapeutics, Inc. Common Stock takes out the full calculated possible swing range there will be an estimated 6.15% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $41.67 (1.68%) than the support at $40.06 (2.24%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Rapport Therapeutics, Inc. Common Stock stock A Buy?

Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Buy candidate.

Current score: 4.189 Buy Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on August 3, 2026 - $41.53 ( 1.33%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk